Cargando…
From targeted therapy to a novel way: Immunogenic cell death in lung cancer
Lung cancer (LC) is one of the most incident malignancies and a leading cause of cancer mortality worldwide. Common tumorigenic drivers of LC mainly include genetic alterations of EGFR, ALK, KRAS, BRAF, ROS1, and MET. Small inhibitory molecules and antibodies selectively targeting these alterations...
Autores principales: | Xu, Jiawei, Xiong, Yiyi, Xu, Zhou, Xing, Hongquan, Zhou, Lingyun, Zhang, Xinyi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9816397/ https://www.ncbi.nlm.nih.gov/pubmed/36619616 http://dx.doi.org/10.3389/fmed.2022.1102550 |
Ejemplares similares
-
Afzelin induces immunogenic cell death against lung cancer by targeting NQO2
por: Xia, Lei, et al.
Publicado: (2023) -
Immunogenic cell death-based prognostic model for predicting the response to immunotherapy and common therapy in lung adenocarcinoma
por: Zhou, Xiang, et al.
Publicado: (2023) -
Targeting immunogenic cell death in cancer
por: Ahmed, Asma, et al.
Publicado: (2020) -
A novel immunogenic cell death signature for the prediction of prognosis and therapies in glioma
por: Zhang, Jianhua, et al.
Publicado: (2023) -
Immunogenic Cell Death in Hematological Malignancy Therapy
por: Liu, Zhaoyun, et al.
Publicado: (2023)